SMS Pharmaceuticals Ltd Revises Schedule for 38th Annual General Meeting and Dividend Record Date
SMS Pharmaceuticals Ltd has announced revisions to the schedule for its 38th Annual General Meeting (AGM), the corresponding Book Closure period, and the Record Date for determining members eligible to receive dividends for the financial year 2025-26.The Board of Directors of the company approved these changes due to administrative and scheduling constraints.
The 38th Annual General Meeting, covering the financial year ended March 31, 2026, is now scheduled to be held on Tuesday, September 29, 2026. The meeting will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
The company set Tuesday, September 22, 2026, as the Record Date for dividend eligibility.
The schedule details, including previous dates and the revised timings for the AGM and dividend eligibility, are as follows:
| Event | Original Date | Revised Date / Period |
|---|---|---|
| 38th AGM | Wednesday, September 23, 2026 | Tuesday, September 29, 2026 |
| Dividend Record Date | Wednesday, September 16, 2026 | Tuesday, September 22, 2026 |
| Book Closure | N/A | Wednesday, September 23, 2026 to Tuesday, September 29, 2026 (inclusive) |
The Book Closure period for the Register of Members and Share Transfer Books is set for Wednesday, September 23, 2026, through Tuesday, September 29, 2026.
The company confirmed that if the dividend for the financial year 2025-26 is approved at the ensuing AGM, it will be paid within the stipulated period. All other items detailed in the company's prior intimation dated July 31, 2026, remain unchanged.
SMSPHARMA Stock Price Movement
Shares of SMS Pharmaceuticals Limited are edging higher to ₹360.75 as of 12:10 PM today, gaining 0.85% and moving up ₹3.05 in live trading. The stock price trades within a day range that saw 75,468 shares traded in volume, hitting a high of ₹362.4.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.